Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-23T10:28:54.997Z Has data issue: false hasContentIssue false
  • English
  • Français

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

Published online by Cambridge University Press:  15 March 2005

A. IOB ,
G. BRIANTI ,
E. ZAMPARO  and
T. GALLO
A. IOB
Affiliation:
Azienda Servizi Sanitari no. 3, Gemona, Alto Friuli, Italy
G. BRIANTI
Affiliation:
Azienda Servizi Sanitari no. 4, Udine, Medio Friuli, Italy
E. ZAMPARO
Affiliation:
Azienda Servizi Sanitari no. 6, Pordenone, Friuli Occidentale, Italy
T. GALLO
Affiliation:
Azienda Servizi Sanitari no. 5, Palmanova, Bassa Friulana, Italy
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We evaluated whether the increased immunogenicity provided by an MF59-adjuvant influenza vaccine translates into increased protection among the elderly. Residents of 25 long-term care facilities received either the adjuvant or a non-adjuvant vaccine. The odds ratios (OR) of influenza-like illness were calculated for non-adjuvant vs. adjuvant vaccine recipients, also stratifying for chronic cardiovascular, respiratory, and renal diseases. The risk was higher for the non-adjuvant vaccine recipients and highest for those with respiratory disease (OR 2·27, 95% CI 1·09–4·82) and cardiovascular disease (OR 1·88; 95% CI 1·31–2·72). In this study the MF59-adjuvant vaccine provided superior clinical protection among the elderly, especially those with chronic diseases.

Type
Research Article
Information
Epidemiology & Infection , Volume 133 , Issue 4 , August 2005 , pp. 687 - 693
Copyright
2005 Cambridge University Press